CRISPR Therapeutics AG Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
CRISPR Therapeutics AG quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • CRISPR Therapeutics AG Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$126M, a 62.6% decline year-over-year.
  • CRISPR Therapeutics AG Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$266M, a 36.1% increase year-over-year.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2023 was -$154M, a 76.4% increase from 2022.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2022 was -$650M, a 272% decline from 2021.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2021 was $378M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$266M -$126M -$48.7M -62.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$217M -$117M -$63.5M -120% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-05
Q4 2023 -$154M $89.3M +$200M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 -$354M -$112M +$62.4M +35.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 -$416M -$77.7M +$108M +58.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$524M -$53.1M +$126M +70.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-05
Q4 2022 -$650M -$111M +$30.7M +21.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 -$681M -$175M -$47.4M -37.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$633M -$186M -$945M -124% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 $312M -$179M -$66.1M -58.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-06
Q4 2021 $378M -$141M -$34.2M -32% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $412M -$127M -$34.7M -37.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $447M $759M +$839M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-01
Q1 2021 -$392M -$113M -$43.4M -62.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-01
Q4 2020 -$349M -$107M -$138M -450% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-16
Q3 2020 -$211M -$92.4M -$231M -167% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $19.6M -$79.7M -$26M -48.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-03
Q1 2020 $45.5M -$69.7M -$21.3M -44% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-03
Q4 2019 $66.9M $30.5M +$78.1M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-16
Q3 2019 -$11.3M $138M +$189M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-16
Q2 2019 -$200M -$53.7M -$15.3M -39.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-16
Q1 2019 -$185M -$48.4M -$20.1M -71.1% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-16
Q4 2018 -$165M -$47.6M -$47.7M -34093% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-12
Q3 2018 -$117M -$50.7M -$26M -105% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-12
Q2 2018 -$91.2M -$38.4M -$16.1M -72% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-12
Q1 2018 -$75.2M -$28.3M -$6.83M -31.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-12
Q4 2017 -$68.4M $140K -$17M -99.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 -$51.4M -$24.7M -$10M -68.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 -$41.4M -$22.3M -$5.16M -30.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 -$36.2M -$21.5M -$13M -154% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 -$23.2M $17.1M +$29.4M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$52.5M -$14.7M -$8.33M -131% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$44.2M -$17.2M -$13.5M -371% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$30.7M -$8.44M -$5.2M -161% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$25.5M -$12.3M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$6.35M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$3.64M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$3.24M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.